Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma

Omaima Mohamed Ali,1 Hussein Ahmed El Amin,2 Yousry Lotfy Sharkawy,1 Adnan Ahmed Mohamed Ali,3 Emad Farah Mohammed Kholef,4 Wael Abd Elgwad Elsewify1 1Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, Egypt; 2Internal Medicine Department, Faculty of Medicine, Assuit Univers...

Full description

Bibliographic Details
Main Authors: Ali OM, El Amin HA, Sharkawy YL, Mohamed Ali AA, Kholef EFM, Elsewify WAE
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:International Journal of General Medicine
Subjects:
hcc
afp
Online Access:https://www.dovepress.com/golgi-protein-73-versus-alpha-fetoprotein-as-a-new-biomarker-in-early--peer-reviewed-article-IJGM
id doaj-fdb4a37560744a2ba040b5b3f5a159e1
record_format Article
spelling doaj-fdb4a37560744a2ba040b5b3f5a159e12020-11-25T03:21:59ZengDove Medical PressInternational Journal of General Medicine1178-70742020-05-01Volume 1319320053841Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular CarcinomaAli OMEl Amin HASharkawy YLMohamed Ali AAKholef EFMElsewify WAEOmaima Mohamed Ali,1 Hussein Ahmed El Amin,2 Yousry Lotfy Sharkawy,1 Adnan Ahmed Mohamed Ali,3 Emad Farah Mohammed Kholef,4 Wael Abd Elgwad Elsewify1 1Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, Egypt; 2Internal Medicine Department, Faculty of Medicine, Assuit University, Assuit, Egypt; 3Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assuit University, Assuit, Egypt; 4Clinical Pathology Department, Faculty of Medicine, Aswan University, Aswan, EgyptCorrespondence: Wael Abd Elgwad ElsewifyDepartment of Internal Medicine, Faculty of Medicine, Aswan University, Aswan 81528, EgyptTel +201001657295Fax +20973480449Email waelelsewify@yahoo.comBackground: Screening of early hepatocellular carcinoma (HCC) diagnosis is the greatest challenge for hepatologists. Alpha-fetoprotein (AFP) is the most common non-invasive biomarker used in HCC diagnosis.Objectives and Aims: To make a comparison between the new biomarker Golgi protein 73 (GP73) versus the standard biomarker AFP in the diagnosis of HCC.Methods: Our study was a case–control study, and 60 patients were included in the study. They were divided into two groups: 1) HCC patients with either chronic HBV or HCV infection (n=30); and 2) non-HCC patients with HBV or HCV infection who had either chronic hepatitis or liver cirrhosis (n=30). In addition, 30 healthy volunteers were included as a control group. Patients were subjected to liver function tests, kidney function tests, serum Golgi protein 73 and AFP levels. Imaging diagnosis of HCC was done by computed tomography (CT) or magnetic resonance imaging (MRI) based on American Association for the Study of Liver Diseases (AASLD) practice guidelines.Results: Statistically significant differences between groups in terms of serum AFP (p< 0.001) and GP73 (p< 0.001) were found. Non-HCC patients (chronic hepatitis and liver cirrhosis) and HCC patients had significantly higher AFP and GP73 than the control group. In addition, patients with HCC had significantly higher AFP and GP73 than chronic hepatitis and cirrhotic patients. GP73 had higher diagnostic performance than AFP. At a cut-off value of ≥ 8.4 ng/mL, GP73 yielded a sensitivity of 86.7% and specificity of 89% for the discrimination between HCC and normal populations. Similarly, at a cut-off value of ≥ 8.45 ng/mL, GP73 yielded a sensitivity of 83.3% and specificity of 84% for the discrimination between HCC patients and non-HCC patients. On the other hand, AFP at a cut-off value of ≥ 2.4 ng/mL yielded a sensitivity of 75.4% and specificity of 90% for the discrimination between HCC and normal populations; and at a cut-off value of ≥ 20.85 ng/mL, AFP yielded a sensitivity of 72.2% and specificity of 86.2% for the discrimination between HCC and non-HCC patients.Conclusion: Golgi protein 73 is a promising and accurate biomarker for early detection of HCC.Keywords: liver cirrhosis, HCC, AFP, Golgi protein 73https://www.dovepress.com/golgi-protein-73-versus-alpha-fetoprotein-as-a-new-biomarker-in-early--peer-reviewed-article-IJGMliver cirrhosishccafpgolgi protein 73.
collection DOAJ
language English
format Article
sources DOAJ
author Ali OM
El Amin HA
Sharkawy YL
Mohamed Ali AA
Kholef EFM
Elsewify WAE
spellingShingle Ali OM
El Amin HA
Sharkawy YL
Mohamed Ali AA
Kholef EFM
Elsewify WAE
Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
International Journal of General Medicine
liver cirrhosis
hcc
afp
golgi protein 73.
author_facet Ali OM
El Amin HA
Sharkawy YL
Mohamed Ali AA
Kholef EFM
Elsewify WAE
author_sort Ali OM
title Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
title_short Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
title_full Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
title_fullStr Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
title_full_unstemmed Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma
title_sort golgi protein 73 versus alpha-fetoprotein as a new biomarker in early diagnosis of hepatocellular carcinoma
publisher Dove Medical Press
series International Journal of General Medicine
issn 1178-7074
publishDate 2020-05-01
description Omaima Mohamed Ali,1 Hussein Ahmed El Amin,2 Yousry Lotfy Sharkawy,1 Adnan Ahmed Mohamed Ali,3 Emad Farah Mohammed Kholef,4 Wael Abd Elgwad Elsewify1 1Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, Egypt; 2Internal Medicine Department, Faculty of Medicine, Assuit University, Assuit, Egypt; 3Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assuit University, Assuit, Egypt; 4Clinical Pathology Department, Faculty of Medicine, Aswan University, Aswan, EgyptCorrespondence: Wael Abd Elgwad ElsewifyDepartment of Internal Medicine, Faculty of Medicine, Aswan University, Aswan 81528, EgyptTel +201001657295Fax +20973480449Email waelelsewify@yahoo.comBackground: Screening of early hepatocellular carcinoma (HCC) diagnosis is the greatest challenge for hepatologists. Alpha-fetoprotein (AFP) is the most common non-invasive biomarker used in HCC diagnosis.Objectives and Aims: To make a comparison between the new biomarker Golgi protein 73 (GP73) versus the standard biomarker AFP in the diagnosis of HCC.Methods: Our study was a case–control study, and 60 patients were included in the study. They were divided into two groups: 1) HCC patients with either chronic HBV or HCV infection (n=30); and 2) non-HCC patients with HBV or HCV infection who had either chronic hepatitis or liver cirrhosis (n=30). In addition, 30 healthy volunteers were included as a control group. Patients were subjected to liver function tests, kidney function tests, serum Golgi protein 73 and AFP levels. Imaging diagnosis of HCC was done by computed tomography (CT) or magnetic resonance imaging (MRI) based on American Association for the Study of Liver Diseases (AASLD) practice guidelines.Results: Statistically significant differences between groups in terms of serum AFP (p< 0.001) and GP73 (p< 0.001) were found. Non-HCC patients (chronic hepatitis and liver cirrhosis) and HCC patients had significantly higher AFP and GP73 than the control group. In addition, patients with HCC had significantly higher AFP and GP73 than chronic hepatitis and cirrhotic patients. GP73 had higher diagnostic performance than AFP. At a cut-off value of ≥ 8.4 ng/mL, GP73 yielded a sensitivity of 86.7% and specificity of 89% for the discrimination between HCC and normal populations. Similarly, at a cut-off value of ≥ 8.45 ng/mL, GP73 yielded a sensitivity of 83.3% and specificity of 84% for the discrimination between HCC patients and non-HCC patients. On the other hand, AFP at a cut-off value of ≥ 2.4 ng/mL yielded a sensitivity of 75.4% and specificity of 90% for the discrimination between HCC and normal populations; and at a cut-off value of ≥ 20.85 ng/mL, AFP yielded a sensitivity of 72.2% and specificity of 86.2% for the discrimination between HCC and non-HCC patients.Conclusion: Golgi protein 73 is a promising and accurate biomarker for early detection of HCC.Keywords: liver cirrhosis, HCC, AFP, Golgi protein 73
topic liver cirrhosis
hcc
afp
golgi protein 73.
url https://www.dovepress.com/golgi-protein-73-versus-alpha-fetoprotein-as-a-new-biomarker-in-early--peer-reviewed-article-IJGM
work_keys_str_mv AT aliom golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
AT elaminha golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
AT sharkawyyl golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
AT mohamedaliaa golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
AT kholefefm golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
AT elsewifywae golgiprotein73versusalphafetoproteinasanewbiomarkerinearlydiagnosisofhepatocellularcarcinoma
_version_ 1724611946922115072